Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Metastatic Solid Tumors 1Cholangiocarcinoma 1Camurati-Engelmann Syndrome 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 39Docetaxel 38palbociclib 36Carboplatin 33Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × bintrafusp alfa protein, human × Clear all
NCT04756505 2023-12-27

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT03524170 2022-03-07

Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
24 enrolled
Breast

Breast Neoplasms

NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 10 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡